Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer

Original Citation:
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer / Meattini, Icro; Desideri, Isacco; Scotti, Vieri; Simontacchi, Gabriele; Livi, Lorenzo. - In: THE BREAST. - ISSN 0960-9776. - ELETTRONICO. - 42:(2018), pp. 1-2-2. [10.1016/j.breast.2018.08.096]

Availability:
This version is available at: 2158/1134482 since: 2018-09-12T18:27:20Z

Published version:
DOI: 10.1016/j.breast.2018.08.096

Terms of use:
Open Access
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)

Publisher copyright claim:
Conformità alle politiche dell'editore / Compliance to publisher's policies
Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.
This version of the publication conforms to the publisher's copyright policies.
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer

1 Icro Meattini, 1Isacco Desideri, 1Vieri Scotti, 1Gabriele Simontacchi, and 1Lorenzo Livi

2 *Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy

3 *Corresponding Author:
4 Icro Meattini, MD
5 Radiation Oncology Unit, Oncology Department
6 Azienda Ospedaliero-Universitaria Careggi, University of Florence
7 Largo G. A. Brambilla 3, 50134, Florence, Italy
8 Tel: +39-055-7947719; fax +39-055-4379930
9 e-mail: icro.meattini@unifi.it

10 Keywords: breast cancer; concomitant radiotherapy; ribociclib; safety.
Abstract

Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach.

There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC.
Ribociclib (Kisqali®; Novartis, Basel, Switzerland) is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone [1].

However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach. Nevertheless, inhibition of CDK4/6 has shown to exert a protective effect on radiation-induced gastrointestinal toxicity in a preclinical model [2]. Therefore, the association of this class of drugs with RT could represent a beneficial combination.

There are no available published data regarding the combination of ribociclib and palliative RT in a clinical setting. A recently published preliminary report on five patients treated with palbociclib and radiation at the Institut Curie (Paris, France) showed encouraging results [3].

We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib (600 mg once daily; 3 x 200-mg tablets; 21 consecutive days of treatment, followed by 7 days off treatment) plus letrozole (2.5 mg tablet; once daily throughout the 28-day cycle) as first-line treatment for MBC.

Main patients’ series characteristics are summarized in Table 1. In all cases, RT was prescribed with palliative/analgesic intent due to symptomatic bone metastases. Two patients had bone-only disease, three patients both bone and visceral disease (two lung, one liver).

Hematological and non-hematological toxicities were assessed during the second 21-days cycle of ribociclib, following the concomitant delivery of RT and the first cycle of ribociclib. Major recorded adverse events confirmed a safety profile of the combined approach in line with main published data [1,4,5]. No RT course was suspended, and all patients had pain relief.

Ribociclib treatment suspension was required in two cases, for two weeks. Treatment recovery (first dose reduction; 400 mg; 2 x 200-mg tablets) was observed in both cases, while letrozole was never suspended.

At time of the present analysis, all the patients are still on first-line treatment: three patients received four cycles and two patients five cycles of ribociclib. At 3-month assessment (clinical visit, thorax/abdomen computed tomography scan, bone scan), three stable disease and two partial response were observed.

Even though the toxicity profile of concomitant ribociclib and RT requires further large investigations, our very preliminary data showed encouraging results and a safety in line with data deriving from pivotal trials. Prospective cooperative data collection initiative on combined strategy is warranted.
Conflicts of interest statement
None declared.

References


Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer

1 Icro Meattini, 1Isacco Desideri, 1Vieri Scotti, 1Gabriele Simontacchi, and 1Lorenzo Livi

2 Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Università Careggi, University of Florence, Florence, Italy

*Corresponding Author:

Icro Meattini, MD
Radiation Oncology Unit, Oncology Department
Azienda Ospedaliero-Università Careggi, University of Florence
Largo G. A. Brambilla 3, 50134, Florence, Italy
Tel: +39-055-7947719; fax +39-055-4379930

1 e-mail: icro.meattini@unifi.it

Keywords: breast cancer; concomitant radiotherapy; ribociclib; safety.
Abstract

Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach.

There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC.
Ribociclib (Kisqali®; Novartis, Basel, Switzerland) is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone [1].

However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach. Nevertheless, inhibition of CDK4/6 has shown to exert a protective effect on radiation-induced gastrointestinal toxicity in a preclinical model [2]. Therefore, the association of this class of drugs with RT could represent a beneficial combination.

There are no available published data regarding the combination of ribociclib and palliative RT in a clinical setting. A recently published preliminary report on five patients treated with palbociclib and radiation at the Institut Curie (Paris, France) showed encouraging results [3].

We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib (600 mg once daily; 3 x 200-mg tablets; 21 consecutive days of treatment, followed by 7 days off treatment) plus letrozole (2.5 mg tablet; once daily throughout the 28-day cycle) as first-line treatment for MBC.

Main patients’ series characteristics are summarized in Table 1. In all cases, RT was prescribed with palliative/analgesic intent due to symptomatic bone metastases. Two patients had bone-only disease, three patients both bone and visceral disease (two lung, one liver).

Hematological and non-hematological toxicities were assessed during the second 21-days cycle of ribociclib, following the concomitant delivery of RT and the first cycle of ribociclib. Major recorded adverse events confirmed a safety profile of the combined approach in line with main published data [1,4,5]. No RT course was suspended, and all patients had pain relief.

Ribociclib treatment suspension was required in two cases, for two weeks. Treatment recovery (first dose reduction; 400 mg; 2 x 200-mg tablets) was observed in both cases, while letrozole was never suspended.

At time of the present analysis, all the patients are still on first-line treatment: three patients received four cycles and two patients five cycles of ribociclib. At 3-month assessment (clinical visit, thorax/abdomen computed tomography scan, bone scan), three stable disease and two partial response were observed.

Even though the toxicity profile of concomitant ribociclib and RT requires further large investigations, our very preliminary data showed encouraging results and a safety in line with data deriving from pivotal trials. Prospective cooperative data collection initiative on combined strategy is warranted.
Conflicts of interest statement

None declared.

References


Table 1. Main patients and treatments characteristics.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>PS</th>
<th>RT treated site</th>
<th>Dose (Gy)/Fx</th>
<th>Technique</th>
<th>Ribociclib cycle</th>
<th>G3-4 hematological toxicity*</th>
<th>G3-4 non hematological toxicity*</th>
<th>RT suspension required</th>
<th>Pain relief°</th>
<th>Ribociclib suspension required*</th>
<th>Weeks of suspension</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>71</td>
<td>0</td>
<td>Left femoral neck</td>
<td>30/5</td>
<td>VMAT</td>
<td>1</td>
<td>Neutropenia</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>55</td>
<td>0</td>
<td>Bilateral femoral</td>
<td>20/5</td>
<td>3DCRT</td>
<td>1</td>
<td>Neutropenia</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>76</td>
<td>2</td>
<td>Right hip</td>
<td>20/5</td>
<td>3DCRT</td>
<td>1</td>
<td>No</td>
<td>Diarrhea</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>79</td>
<td>1</td>
<td>Lumbar spine (L2-L3)</td>
<td>20/5</td>
<td>3DCRT</td>
<td>1</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>36</td>
<td>0</td>
<td>Cervical/thoracic</td>
<td>20/5</td>
<td>3DCRT</td>
<td>1</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: PS, performance status; Dose/fx, total dose (Gy)/number of fractions; G3-4, grade 3–4; RT, radiotherapy; VMAT, volumetric modulated arc therapy; 3DCRT, 3-dimensional conformal radiotherapy.

*Toxicity recorded after the cycle of combined treatment ribociclib/letrozole with palliative radiation.

°If pain at palliative radiation start.
Click here to download Additional Files (Article Transfer): Highlights_rev.docx